Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment Of Patients (Pts) With Advanced Squamous Cell Carcinoma (Scc) Of The Lung Following First-Line Platinum-Based Chemotherapy: Patient-Reported Outcome (Pro) Data From The Lux-Lung 8 Phase Iii Global Trial.

8100 Background: A is an irreversible ErbB family blocker that has shown clinical activity in pts with SCC of the head/neck and lung. The LUX-Lung 8 Phase III global trial compared A and E in pts with SCC of the lung following failure of platinum-based chemotherapy. Between Mar 2012 and Jan 2014, 795 stage IIIB/IV SCC pts were randomized 1:1 to receive A (40 mg/day) or E (150 mg/day) until progression. The primary endpoint of PFS, assessed after 414 events, was significantly higher for A than E (median: 2.4 vs 1.9 months; HR [95% CI]: 0.82 [0.68–1.00]; p = 0.04). PRO analyses of the PFS dataset are presented here. Updated PRO analysis of the OS dataset (to be undertaken after 632 deaths) will be available at the meeting. Methods: PROs were collected every 28 days until progression using the EORTC QLQ-C30/LC13 questionnaires. Percentage of pts improved on therapy, time-to-deterioration (TTD) and changes over time were analyzed for the pre-specified SCC symptoms: cough, dyspnea, and pain. Results: Improveme...